Cullinan Therapeutics (CGEM) Cash from Investing Activities (2020 - 2026)

Cullinan Therapeutics' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $32.4 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 11.93% year-over-year to $32.4 million; the TTM figure through Mar 2026 stood at $175.6 million (up 256.14% YoY), while the FY2025 annual figure was $180.0 million, up 232.04% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $32.4 million, up from $22.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $300.9 million in Q2 2022, with the low at -$185.1 million in Q2 2024.
• The 5-year median for Cash from Investing Activities is $19.9 million (2024), against an average of $21.2 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities jumped 294.61% in 2022, then sank 1628.59% in 2024.
• Cullinan Therapeutics' Cash from Investing Activities stood at -$28.6 million in 2022, then surged by 279.9% to $51.5 million in 2023, then tumbled by 68.98% to $16.0 million in 2024, then soared by 40.26% to $22.4 million in 2025, then jumped by 44.76% to $32.4 million in 2026.
• Business Quant data shows CGEM's Cash from Investing Activities at $32.4 million in Q1 2026, $22.4 million in Q4 2025, and $67.4 million in Q3 2025.